Webinar: Lymphoma and CLL Research Highlights from ASH 2021
Tuesday, April 5, 2022
2:00-3:30 pm PST; 5:00 – 6:30 pm EST
Each year, scientists and medical professionals from around the world gather together to share research and clinical updates in hematology at the American Society of Hematology (ASH) conference. With more than 18,000 members from nearly 100 countries, ASH is the world’s largest professional society serving clinicians and scientists who are working to conquer blood diseases. At the conference, advancements in lymphoma and CLL treatments and care are presented, helping Canadian clinicians to understand and prepare for changes in treatment approaches as new therapies come to market.
At this patient-centered educational webinar, Dr. Laurie Sehn and Dr. Alina Gerrie will provide an overview of research updates on the diagnosis and treatment of lymphoma including Non-Hodgkin’s Lymphomas (B-Cell and T-Cell), Hodgkin Lymphoma, and Chronic Lymphocytic Leukemia, based on the results presented at the ASH conference in December 2021.
Dr. Laurie Sehn
Professor, British Columbia Cancer Centre
Medical Oncologist, BC Cancer Agency
Dr. Alina Gerrie
Assistant Professor, University of British Columbia
Hematologist, BC Cancer Agency
Dr. Laurie Sehn is a Clinical Professor with the British Columbia Cancer Centre for Lymphoid Cancer and University of British Columbia, Canada. She has been a medical oncologist and clinical investigator at BC Cancer since 1998, and is currently the Chair of the Lymphoma Tumour Group. Dr. Sehn graduated from McGill Medical School, Montreal, Canada and received her training in Internal Medicine at Columbia Presbyterian Medical Center, Columbia University, New York, USA. She was trained in Haematology-Oncology at Brigham and Women’s Hospital and the Dana-Farber Cancer Institute, Harvard University, Boston, and received a Masters of Public Health degree from Harvard School of Public Health, Harvard University. Dr. Sehn is Chair of the medical advisory board for the International Lymphoma Coalition. Dr. Sehn also serves as co-chair of the Lymphoma Site of the Canadian Cancer Trials Group and co-chair of the Lunenburg Lymphoma Biomarker Consortium.
Dr. Alina Gerrie is a hematologist and assistant professor in the Divisions of Hematology and Medical Oncology at the University of British Columbia (UBC). She is a member of the Lymphoma Tumour Group at BC Cancer and a clinician investigator with the Centre for Lymphoid Cancer at the BC Cancer Research Centre. Dr. Gerrie earned her medical degree and internal medicine specialization at the University of Toronto, followed by a hematology specialization at UBC. She completed a fellowship through the Royal College of Physicians and Surgeons of Canada Clinical Investigator Program and earned a Master of Public Health from Harvard University. Dr. Gerrie is involved in translational, clinical trial and outcomes-based research related to leukemia and lymphoma. Other academic interests include the investigation of novel therapeutics and stem cell transplant for chronic lymphocytic leukemia (CLL) and lymphoma and improving long-term outcomes for lymphoma and stem cell transplant survivors.